The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression

The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression

Since type and duration of an appropriate adjuvant chemotherapy in early-stage ovarian cancer (OC) are still being debated, novel markers for a better stratification of these patients are of utmost importance for the design of an improved chemotherapeutical strategy. In contrast to numerous cancer s...

Full description

Bibliographic Details
Main Authors: Franz Rödel, Shengtao Zhou, Balász Győrffy, Monika Raab, Mourad Sanhaji, Ranadip Mandal, Daniel Martin, Sven Becker, Klaus Strebhardt
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
polo-like kinase 1
Ki-67/MIB1
ovarian cancer
prognosis
mRNA and protein expression
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.558932/full
id doaj-93cf63b38a824a33a0f7a987b5777ec1
record_format Article
spelling doaj-93cf63b38a824a33a0f7a987b5777ec12020-11-25T03:44:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.558932558932The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein ExpressionFranz Rödel0Franz Rödel1Franz Rödel2Franz Rödel3Shengtao Zhou4Balász Győrffy5Balász Győrffy6Monika Raab7Mourad Sanhaji8Ranadip Mandal9Daniel Martin10Sven Becker11Klaus Strebhardt12Klaus Strebhardt13Klaus Strebhardt14Department of Radiotherapy and Oncology, University Hospital, Goethe-University, Frankfurt am Main, GermanyFrankfurt Cancer Institute, Goethe-University, Frankfurt am Main, GermanyGerman Cancer Research Center (DKFZ), Heidelberg, GermanyGerman Cancer Consortium (DKTK) Partner Site: Frankfurt, Frankfurt am Main, GermanyState Key Laboratory of Biotherapy, Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu, ChinaDepartment of Bioinformatics and 2nd Department of Pediatrics, Semmelweis University, Budapest, HungaryTTK Cancer Biomarker Research Group, Budapest, HungaryDepartment of Gynecology, University Hospital, Goethe-University, Frankfurt am Main, GermanyDepartment of Gynecology, University Hospital, Goethe-University, Frankfurt am Main, GermanyDepartment of Gynecology, University Hospital, Goethe-University, Frankfurt am Main, GermanyDepartment of Radiotherapy and Oncology, University Hospital, Goethe-University, Frankfurt am Main, GermanyDepartment of Gynecology, University Hospital, Goethe-University, Frankfurt am Main, GermanyGerman Cancer Research Center (DKFZ), Heidelberg, GermanyGerman Cancer Consortium (DKTK) Partner Site: Frankfurt, Frankfurt am Main, GermanyDepartment of Gynecology, University Hospital, Goethe-University, Frankfurt am Main, GermanySince type and duration of an appropriate adjuvant chemotherapy in early-stage ovarian cancer (OC) are still being debated, novel markers for a better stratification of these patients are of utmost importance for the design of an improved chemotherapeutical strategy. In contrast to numerous cancer studies on cellular proliferation based on the immunohistochemistry-driven evaluation of protein expression, we compared mRNA and protein expression of two independent markers of cellular proliferation, Ki-67 and Plk1, in a large cohort of 243 early-stage OC and their relationship with clinicopathological features and survival. Based on marker expression we demonstrate that early-stage OC patients (stages I/II, low-grade, serous) with high expression (Ki-67, Plk1) had a significantly shorter progression-free survival (PFS) and overall survival (OS) compared to patients with low expression (Ki-67, Plk1). Remarkably, based on mRNA expression this significant difference got lost in advanced stages (III/IV): At least for PFS, high levels of Ki-67 and Plk1 correlate with moderately better survival compared to patients with low expressing tumors. Our data suggest that in addition to Ki-67, Plk1 is a novel marker for the stratification of early-stage OC patients to maximize therapeutic efforts. Both, Ki-67 and Plk1, seem to be better suited in early-stages (I/II) as therapeutical targets compared to advanced-stages (III/IV) OC.https://www.frontiersin.org/article/10.3389/fonc.2020.558932/fullpolo-like kinase 1Ki-67/MIB1ovarian cancerprognosismRNA and protein expression
collection DOAJ
language English
format Article
sources DOAJ
author Franz Rödel
Franz Rödel
Franz Rödel
Franz Rödel
Shengtao Zhou
Balász Győrffy
Balász Győrffy
Monika Raab
Mourad Sanhaji
Ranadip Mandal
Daniel Martin
Sven Becker
Klaus Strebhardt
Klaus Strebhardt
Klaus Strebhardt
spellingShingle Franz Rödel
Franz Rödel
Franz Rödel
Franz Rödel
Shengtao Zhou
Balász Győrffy
Balász Győrffy
Monika Raab
Mourad Sanhaji
Ranadip Mandal
Daniel Martin
Sven Becker
Klaus Strebhardt
Klaus Strebhardt
Klaus Strebhardt
The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
Frontiers in Oncology
polo-like kinase 1
Ki-67/MIB1
ovarian cancer
prognosis
mRNA and protein expression
author_facet Franz Rödel
Franz Rödel
Franz Rödel
Franz Rödel
Shengtao Zhou
Balász Győrffy
Balász Győrffy
Monika Raab
Mourad Sanhaji
Ranadip Mandal
Daniel Martin
Sven Becker
Klaus Strebhardt
Klaus Strebhardt
Klaus Strebhardt
author_sort Franz Rödel
title The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
title_short The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
title_full The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
title_fullStr The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
title_full_unstemmed The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression
title_sort prognostic relevance of the proliferation markers ki-67 and plk1 in early-stage ovarian cancer patients with serous, low-grade carcinoma based on mrna and protein expression
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2020-10-01
description Since type and duration of an appropriate adjuvant chemotherapy in early-stage ovarian cancer (OC) are still being debated, novel markers for a better stratification of these patients are of utmost importance for the design of an improved chemotherapeutical strategy. In contrast to numerous cancer studies on cellular proliferation based on the immunohistochemistry-driven evaluation of protein expression, we compared mRNA and protein expression of two independent markers of cellular proliferation, Ki-67 and Plk1, in a large cohort of 243 early-stage OC and their relationship with clinicopathological features and survival. Based on marker expression we demonstrate that early-stage OC patients (stages I/II, low-grade, serous) with high expression (Ki-67, Plk1) had a significantly shorter progression-free survival (PFS) and overall survival (OS) compared to patients with low expression (Ki-67, Plk1). Remarkably, based on mRNA expression this significant difference got lost in advanced stages (III/IV): At least for PFS, high levels of Ki-67 and Plk1 correlate with moderately better survival compared to patients with low expressing tumors. Our data suggest that in addition to Ki-67, Plk1 is a novel marker for the stratification of early-stage OC patients to maximize therapeutic efforts. Both, Ki-67 and Plk1, seem to be better suited in early-stages (I/II) as therapeutical targets compared to advanced-stages (III/IV) OC.
topic polo-like kinase 1
Ki-67/MIB1
ovarian cancer
prognosis
mRNA and protein expression
url https://www.frontiersin.org/article/10.3389/fonc.2020.558932/full
work_keys_str_mv AT franzrodel theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT franzrodel theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT franzrodel theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT franzrodel theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT shengtaozhou theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT balaszgyorffy theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT balaszgyorffy theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT monikaraab theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT mouradsanhaji theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT ranadipmandal theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT danielmartin theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT svenbecker theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT klausstrebhardt theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT klausstrebhardt theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT klausstrebhardt theprognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT franzrodel prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT franzrodel prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT franzrodel prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT franzrodel prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT shengtaozhou prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT balaszgyorffy prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT balaszgyorffy prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT monikaraab prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT mouradsanhaji prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT ranadipmandal prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT danielmartin prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT svenbecker prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT klausstrebhardt prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT klausstrebhardt prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
AT klausstrebhardt prognosticrelevanceoftheproliferationmarkerski67andplk1inearlystageovariancancerpatientswithserouslowgradecarcinomabasedonmrnaandproteinexpression
_version_ 1724512592921100288

Similar Items